Related Experiment Videos
Sulphinpyrazone metabolism during long-term therapy
British Journal of Clinical Pharmacology
|June 1, 1981
Summary
This study tracked sulphinpyrazone and its metabolites in diabetic patients. The active metabolites found in plasma suggest they contribute significantly to the drug's platelet inhibitory effects during long-term use.
Area of Science:
- Pharmacokinetics and Drug Metabolism
- Clinical Pharmacology
- Diabetology
Background:
- Long-term sulphinpyrazone therapy is used in insulin-requiring diabetics.
- Understanding the pharmacokinetics and metabolite activity is crucial for optimizing treatment.
Purpose of the Study:
- To quantify plasma concentrations and urinary excretion of sulphinpyrazone and its metabolites.
- To assess the in vitro platelet inhibitory activity of sulphinpyrazone and its metabolites.
Main Methods:
- Blood and urine samples were collected from eight diabetic patients on long-term sulphinpyrazone treatment.
- Plasma concentrations were measured at baseline and 2 hours post-dose.
- Urinary excretion and glucuronide conjugation were analyzed.
Main Results:
- Significant correlations were observed between plasma concentrations of sulphinpyrazone, its sulphide, and p-OH-sulphide metabolites.
- Urinary excretion of sulphinpyrazone varied (1-30%), while metabolites were generally <1%, except for the sulphone metabolite (up to 3%).
- Both sulphide and sulphone metabolites demonstrated higher in vitro platelet inhibition than sulphinpyrazone.
Conclusions:
- Sulphinpyrazone metabolites, particularly the sulphide and sulphone, are likely responsible for the majority of the drug's platelet inhibitory activity in plasma during chronic therapy.
- These findings have implications for understanding the efficacy and safety of sulphinpyrazone in diabetic patients.